Summary | |
---|---|
Symbol | CD48 |
Name | CD48 molecule |
Aliases | BLAST; mCD48; hCD48; SLAMF2; BCM1; CD48 antigen (B-cell membrane protein); BLAST1; MEM-102; B-lymphocyte act ...... |
Chromosomal Location | 1q21.3-q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cell membrane Lipid-anchor, GPI-anchor |
Domain |
PF13895 Immunoglobulin domain PF07686 Immunoglobulin V-set domain |
Function |
Ligand for CD2. Might facilitate interaction between activated lymphocytes. Probably involved in regulating T-cell activation. |
Biological Process |
GO:0002250 adaptive immune response GO:0002819 regulation of adaptive immune response GO:0050900 leukocyte migration |
Molecular Function | - |
Cellular Component |
GO:0031225 anchored component of membrane GO:0045121 membrane raft GO:0098589 membrane region GO:0098857 membrane microdomain |
KEGG |
hsa04650 Natural killer cell mediated cytotoxicity |
Reactome |
R-HSA-202733: Cell surface interactions at the vascular wall R-HSA-109582: Hemostasis |
Summary | |
---|---|
Symbol | CD48 |
Name | CD48 molecule |
Aliases | BLAST; mCD48; hCD48; SLAMF2; BCM1; CD48 antigen (B-cell membrane protein); BLAST1; MEM-102; B-lymphocyte act ...... |
Chromosomal Location | 1q21.3-q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between CD48 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between CD48 and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | CD48 |
Name | CD48 molecule |
Aliases | BLAST; mCD48; hCD48; SLAMF2; BCM1; CD48 antigen (B-cell membrane protein); BLAST1; MEM-102; B-lymphocyte act ...... |
Chromosomal Location | 1q21.3-q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of CD48 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | CD48 |
Name | CD48 molecule |
Aliases | BLAST; mCD48; hCD48; SLAMF2; BCM1; CD48 antigen (B-cell membrane protein); BLAST1; MEM-102; B-lymphocyte act ...... |
Chromosomal Location | 1q21.3-q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of CD48 in various data sets.
|
Points in the above scatter plot represent the mutation difference of CD48 in various data sets.
|
Summary | |
---|---|
Symbol | CD48 |
Name | CD48 molecule |
Aliases | BLAST; mCD48; hCD48; SLAMF2; BCM1; CD48 antigen (B-cell membrane protein); BLAST1; MEM-102; B-lymphocyte act ...... |
Chromosomal Location | 1q21.3-q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CD48. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | CD48 |
Name | CD48 molecule |
Aliases | BLAST; mCD48; hCD48; SLAMF2; BCM1; CD48 antigen (B-cell membrane protein); BLAST1; MEM-102; B-lymphocyte act ...... |
Chromosomal Location | 1q21.3-q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CD48. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CD48. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | CD48 |
Name | CD48 molecule |
Aliases | BLAST; mCD48; hCD48; SLAMF2; BCM1; CD48 antigen (B-cell membrane protein); BLAST1; MEM-102; B-lymphocyte act ...... |
Chromosomal Location | 1q21.3-q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CD48. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | CD48 |
Name | CD48 molecule |
Aliases | BLAST; mCD48; hCD48; SLAMF2; BCM1; CD48 antigen (B-cell membrane protein); BLAST1; MEM-102; B-lymphocyte act ...... |
Chromosomal Location | 1q21.3-q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of CD48 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | CD48 |
Name | CD48 molecule |
Aliases | BLAST; mCD48; hCD48; SLAMF2; BCM1; CD48 antigen (B-cell membrane protein); BLAST1; MEM-102; B-lymphocyte act ...... |
Chromosomal Location | 1q21.3-q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between CD48 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | CD48 |
Name | CD48 molecule |
Aliases | BLAST; mCD48; hCD48; SLAMF2; BCM1; CD48 antigen (B-cell membrane protein); BLAST1; MEM-102; B-lymphocyte act ...... |
Chromosomal Location | 1q21.3-q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting CD48 collected from DrugBank database. |
There is no record. |